Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET

Core Viewpoint - Soleno Therapeutics, Inc. will report its second quarter 2025 financial results and operational highlights on August 6, 2025, followed by a conference call to discuss the results and business operations [1]. Financial Results Announcement - The financial results will be released after the close of U.S. financial markets on August 6, 2025 [1]. - A conference call and webcast will take place at 4:30 PM Eastern Time on the same day [2]. Product Information - Soleno's first commercial product, VYKAT XR, is indicated for the treatment of hyperphagia in adults and pediatric patients aged 4 years and older with Prader-Willi syndrome [3][8]. - VYKAT XR is a once-daily oral treatment, previously known as DCCR [8]. Safety Information - VYKAT XR is contraindicated in patients with known hypersensitivity to diazoxide or thiazides [4]. - Hyperglycemia, including diabetic ketoacidosis, has been reported; monitoring of fasting plasma glucose and HbA1c is recommended before and during treatment [5]. - There is a risk of fluid overload and edema; patients with compromised cardiac reserve should use VYKAT XR with caution [6]. Adverse Reactions - Common adverse reactions (≥10% incidence and at least 2% greater than placebo) include hypertrichosis, edema, hyperglycemia, and rash [7].